With the label extension, Eylea 8mg would be the only anti-VEGF approved for a treatment interval of six months. Roche’s Vabysmo became the first bispecific antibody approved for the eye.

An EMA committee has recommended approval of Alvotech’s AVT06, a biosimilar to Bayer’s blockbuster ophthalmology drug Eylea.

The European Commission has cleared the high-strength formulation of Eylea (aflibercept) with an extended treatment interval ...

Novartis ups the ante in the wet AMD market battle with Bayer/Regeneron’s Eylea, launching a trial that will test 16-week dosing for its new antibody brolucizumab.

Findings that U.S. companies can sue foreign rivals despite limited business operations in the country could dissuade drug ...

Eylea and Eylea 8mg – the latter known as Eylea HD in the US – reached combined sales of $9.5bn in 2024. Credit: OleksSH via Shutterstock. Bayer’s retinal disease treatment Eylea (aflibercept) is set ...

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid  Approval based on pivotal results showing improvements in sustained disease remission and ...